Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23799117 | 1.00 | CRBN (0.52) | CRBNDDB1MAPTL3MBTL1 | |
| SCHEMBL31333583 | 0.94 | CRBN (0.46) | CRBNDDB1MAPTL3MBTL1 | |
| SCHEMBL30915140 | 0.90 | CRBN (0.50) | CRBNDDB1 | |
| SCHEMBL30915156 | 0.88 | CRBN (0.47) | CRBNDDB1 | |
| SCHEMBL25218486 | 0.88 | DDB1 (0.53) | CRBNDDB1MAPT | |
| SCHEMBL25268824 | 0.88 | DDB1 (0.53) | CRBNDDB1MAPT | |
| SCHEMBL25273398 | 0.88 | DDB1 (0.53) | CRBNDDB1MAPT | |
| SCHEMBL31334602 | 0.87 | CRBN (0.47) | CRBNDDB1 | |
| SCHEMBL23799119 | 0.87 | CRBN (0.53) | CRBNDDB1 | |
| SCHEMBL31701997 | 0.87 | CRBN (0.53) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250320205-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-116891502-A | EGFR degrading agent | 上海齐鲁制药研究中心有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320205-A1 | STAT6 DEGRADERS | STAT6, STAT1, STAT5B | CRBN 1751/4885DDB1 3708/4885MAPT 1034/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | CRBN 133/4885DDB1 3708/4885MAPT 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.